🚀 VC round data is live in beta, check it out!
Indegene Valuation Multiples
Discover revenue and EBITDA valuation multiples for Indegene and similar public comparables like Vitec Software, U.S. Physical Therapy, Clover Health, Hangzhou Pinming Software and more.
Indegene Overview
About Indegene
Indegene Ltd provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical device companies. It assists them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its portfolio of solutions covers all aspects of commercial, medical, regulatory, and R&D operations for life sciences companies. The company's segments include Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation, and Others. Key revenue is generated from the Omnichannel Activation segment. The company has a presence in India, Europe, and North America, with the majority of revenue coming from North America.
Founded
1998
HQ
Employees
5.0K
Website
Financials (LTM)
EV
$1B
Indegene Financials
Indegene reported last 12-month revenue of $383M and EBITDA of $69M.
In the same LTM period, Indegene generated $138M in gross profit, $69M in EBITDA, and $47M in net income.
Revenue (LTM)
Indegene P&L
In the most recent fiscal year, Indegene reported revenue of $334M and EBITDA of $69M.
Indegene expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $383M | XXX | $334M | XXX | XXX | XXX |
| Gross Profit | $138M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 36% | XXX | — | XXX | XXX | XXX |
| EBITDA | $69M | XXX | $69M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 21% | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $47M | XXX | $48M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 14% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Indegene Stock Performance
Indegene has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Indegene's stock price is $5.26.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.5% | XXX | XXX | XXX | $0.20 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIndegene Valuation Multiples
Indegene trades at 3.0x EV/Revenue multiple, and 16.6x EV/EBITDA.
EV / Revenue (LTM)
Indegene Financial Valuation Multiples
As of April 19, 2026, Indegene has market cap of $1B and EV of $1B.
Equity research analysts estimate Indegene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Indegene has a P/E ratio of 26.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | 3.4x | XXX | XXX | XXX |
| EV/EBITDA | 16.6x | XXX | 16.5x | XXX | XXX | XXX |
| EV/EBIT | 20.0x | XXX | 20.2x | XXX | XXX | XXX |
| EV/Gross Profit | 8.3x | XXX | — | XXX | XXX | XXX |
| P/E | 26.8x | XXX | 26.3x | XXX | XXX | XXX |
| EV/FCF | (38.2x) | XXX | 25.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Indegene Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Indegene Margins & Growth Rates
Indegene's revenue in the last 12 month grew by 19%.
Indegene's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Indegene's rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Indegene's rule of X is 69% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Indegene Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | (1%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 39% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 69% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 77% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Indegene Public Comps
See public comps and valuation multiples for other Healthcare Software and Health Data & Analytics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Indegene | XXX | XXX | XXX | XXX | XXX | XXX |
| Vitec Software | XXX | XXX | XXX | XXX | XXX | XXX |
| U.S. Physical Therapy | XXX | XXX | XXX | XXX | XXX | XXX |
| Clover Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Hangzhou Pinming Software | XXX | XXX | XXX | XXX | XXX | XXX |
| Sphere | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Indegene M&A Activity
Indegene acquired XXX companies to date.
Last acquisition by Indegene was on XXXXXXXX, XXXXX. Indegene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Indegene
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialIndegene Investment Activity
Indegene invested in XXX companies to date.
Indegene made its latest investment on XXXXXXXX, XXXXX. Indegene invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Indegene
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Indegene
| When was Indegene founded? | Indegene was founded in 1998. |
| Where is Indegene headquartered? | Indegene is headquartered in India. |
| How many employees does Indegene have? | As of today, Indegene has over 5K employees. |
| Who is the CEO of Indegene? | Indegene's CEO is Manish Gupta. |
| Is Indegene publicly listed? | Yes, Indegene is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Indegene? | Indegene trades under INDGN ticker. |
| When did Indegene go public? | Indegene went public in 2024. |
| Who are competitors of Indegene? | Indegene main competitors are Vitec Software, U.S. Physical Therapy, Clover Health, Hangzhou Pinming Software. |
| What is the current market cap of Indegene? | Indegene's current market cap is $1B. |
| What is the current revenue of Indegene? | Indegene's last 12 months revenue is $383M. |
| What is the current revenue growth of Indegene? | Indegene revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of Indegene? | Current revenue multiple of Indegene is 3.0x. |
| Is Indegene profitable? | Yes, Indegene is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Indegene? | Indegene's last 12 months EBITDA is $69M. |
| What is Indegene's EBITDA margin? | Indegene's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Indegene? | Current EBITDA multiple of Indegene is 16.6x. |
| What is the current FCF of Indegene? | Indegene's last 12 months FCF is ($30M). |
| What is Indegene's FCF margin? | Indegene's last 12 months FCF margin is (8%). |
| What is the current EV/FCF multiple of Indegene? | Current FCF multiple of Indegene is (38.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.